NeuraWell is a clinical stage company developing safe and highly effective medicines for
Despite the many available mainstream drugs now available, a substantial proportion of patients fail to respond adequately, if at all. Those patients carry a heavy burden of mental and physical suffering, comorbidity with other diseases, shortened life-span, and significant economic and social costs.
(1) It is estimated that more than 30% of MDD patients are treatment resistant and their life expectancy is shortened by 7-11years (a)
(2). Bipolar disorder affects 5.9MM Adult Americans per year (2.9% of the population) (b)
(3). It shortens expected lifespan by 8-10 years and results in a suicide rate as high as 1 in 5 patients (c)
Our goal is to offer personalized medicines that deliver high incidence of meaningful response or remission especially when other treatments have not worked or stopped working.
(a) US DHHS, Agency for Healthcare Research and Quality, “Treatment-Resistant Depression: A Narrative and Systematic Review of Definitions and Methods in Clinical Research Studies” Project ID: PSYT0816, Dec 2016
(b) “Bipolar Disorder”. Depression and Bipolar Alliance. www.BDSA.com
(c) Kessing, LV, Vradi, E, Andersen, PK. Life expectancy in bipolar disorder. Bipolar Disord 2015: 17: 543– 548. © 2015 John Wiley & Sons A/S